The interplay between genetic background and sexual dimorphism of doxorubicin-induced cardiotoxicity

Beshay N. Zordoky; M. Judith Radin; Lois Heller; Anthony Tobias; Ilze Matise; Fred S Apple; Sylvia A. McCune; Leslie C Sharkey

doi:10.1186/s40959-016-0013-3

The interplay between genetic background and sexual dimorphism of doxorubicin-induced cardiotoxicity

Beshay N. Zordoky, M. Judith Radin, Lois Heller, Anthony Tobias, Ilze Matise, Fred S Apple, Sylvia A. McCune, Leslie C Sharkey

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Background: Doxorubicin (DOX) is a very effective anticancer medication that is commonly used to treat hematological malignancies and solid tumors. Nevertheless, DOX is known to have cardiotoxic effects that may lead to cardiac dysfunction and failure. In experimental studies, female animals have been shown to be protected against DOX-induced cardiotoxicity; however, the evidence of this sexual dimorphism is inconclusive in clinical studies. Therefore, we sought to investigate whether genetic background could influence the sexual dimorphism of DOX-induced cardiotoxicity. Methods: Male and female Wistar Kyoto (WKY) and Spontaneous Hypertensive Heart Failure (SHHF) rats were used. DOX was administered in eight doses of 2 mg/kg/week and the rats were followed for an additional 12 weeks. Cardiac function was assessed by trans-thoracic echocardiography, systolic blood pressure was measured by the tail cuff method, and heart and kidney tissues were collected for histopathology. Results: Female sex protected against DOX-induced weight loss and increase in blood pressure in the WKY rats, whereas it protected against DOX-induced cardiac dysfunction and the elevation of cardiac troponin in SHHF rats. In both strains, female sex was protective against DOX-induced nephrotoxicity. There was a strong correlation between DOX-induced renal pathology and DOX-induced cardiac dysfunction. Conclusions: This study highlights the importance of studying the interaction between sex and genetic background to determine the risk of DOX-induced cardiotoxicity. In addition, our findings suggest that DOX-induced nephrotoxicity may play a role in DOX-induced cardiac dysfunction in rodent models.

Original language	English (US)
Article number	4
Journal	Cardio-Oncology
Volume	2
Issue number	1
DOIs	https://doi.org/10.1186/s40959-016-0013-3
State	Published - Dec 2016

Bibliographical note

Funding Information:
Research reported in this publication was supported by an internal Grant-in-aid of Research, Artistry, and Scholarship from the University of Minnesota to LCS, and by a Pre-K Career Development Award from the National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1TR000114 to BNZ. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Publisher Copyright:
© 2016, Zordoky et al.

Keywords

Cardiotoxicity
Doxorubicin
Sexual dimorphism

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1186/s40959-016-0013-3

http://www.cardiooncologyjournal.com/content/2/1/4

Find It

Find It at U of M Libraries

Cite this

@article{f305fc962a584fe581173d33e7d06c65,

title = "The interplay between genetic background and sexual dimorphism of doxorubicin-induced cardiotoxicity",

abstract = "Background: Doxorubicin (DOX) is a very effective anticancer medication that is commonly used to treat hematological malignancies and solid tumors. Nevertheless, DOX is known to have cardiotoxic effects that may lead to cardiac dysfunction and failure. In experimental studies, female animals have been shown to be protected against DOX-induced cardiotoxicity; however, the evidence of this sexual dimorphism is inconclusive in clinical studies. Therefore, we sought to investigate whether genetic background could influence the sexual dimorphism of DOX-induced cardiotoxicity. Methods: Male and female Wistar Kyoto (WKY) and Spontaneous Hypertensive Heart Failure (SHHF) rats were used. DOX was administered in eight doses of 2 mg/kg/week and the rats were followed for an additional 12 weeks. Cardiac function was assessed by trans-thoracic echocardiography, systolic blood pressure was measured by the tail cuff method, and heart and kidney tissues were collected for histopathology. Results: Female sex protected against DOX-induced weight loss and increase in blood pressure in the WKY rats, whereas it protected against DOX-induced cardiac dysfunction and the elevation of cardiac troponin in SHHF rats. In both strains, female sex was protective against DOX-induced nephrotoxicity. There was a strong correlation between DOX-induced renal pathology and DOX-induced cardiac dysfunction. Conclusions: This study highlights the importance of studying the interaction between sex and genetic background to determine the risk of DOX-induced cardiotoxicity. In addition, our findings suggest that DOX-induced nephrotoxicity may play a role in DOX-induced cardiac dysfunction in rodent models.",

keywords = "Cardiotoxicity, Doxorubicin, Sexual dimorphism",

author = "Zordoky, {Beshay N.} and Radin, {M. Judith} and Lois Heller and Anthony Tobias and Ilze Matise and Apple, {Fred S} and McCune, {Sylvia A.} and Sharkey, {Leslie C}",

note = "Funding Information: Research reported in this publication was supported by an internal Grant-in-aid of Research, Artistry, and Scholarship from the University of Minnesota to LCS, and by a Pre-K Career Development Award from the National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1TR000114 to BNZ. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: {\textcopyright} 2016, Zordoky et al.",

year = "2016",

month = dec,

doi = "10.1186/s40959-016-0013-3",

language = "English (US)",

volume = "2",

journal = "Cardio-Oncology",

issn = "2057-3804",

publisher = "BioMed Central Ltd.",

number = "1",

}

TY - JOUR

T1 - The interplay between genetic background and sexual dimorphism of doxorubicin-induced cardiotoxicity

AU - Zordoky, Beshay N.

AU - Radin, M. Judith

AU - Heller, Lois

AU - Tobias, Anthony

AU - Matise, Ilze

AU - Apple, Fred S

AU - McCune, Sylvia A.

AU - Sharkey, Leslie C

N1 - Funding Information: Research reported in this publication was supported by an internal Grant-in-aid of Research, Artistry, and Scholarship from the University of Minnesota to LCS, and by a Pre-K Career Development Award from the National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1TR000114 to BNZ. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: © 2016, Zordoky et al.

PY - 2016/12

Y1 - 2016/12

N2 - Background: Doxorubicin (DOX) is a very effective anticancer medication that is commonly used to treat hematological malignancies and solid tumors. Nevertheless, DOX is known to have cardiotoxic effects that may lead to cardiac dysfunction and failure. In experimental studies, female animals have been shown to be protected against DOX-induced cardiotoxicity; however, the evidence of this sexual dimorphism is inconclusive in clinical studies. Therefore, we sought to investigate whether genetic background could influence the sexual dimorphism of DOX-induced cardiotoxicity. Methods: Male and female Wistar Kyoto (WKY) and Spontaneous Hypertensive Heart Failure (SHHF) rats were used. DOX was administered in eight doses of 2 mg/kg/week and the rats were followed for an additional 12 weeks. Cardiac function was assessed by trans-thoracic echocardiography, systolic blood pressure was measured by the tail cuff method, and heart and kidney tissues were collected for histopathology. Results: Female sex protected against DOX-induced weight loss and increase in blood pressure in the WKY rats, whereas it protected against DOX-induced cardiac dysfunction and the elevation of cardiac troponin in SHHF rats. In both strains, female sex was protective against DOX-induced nephrotoxicity. There was a strong correlation between DOX-induced renal pathology and DOX-induced cardiac dysfunction. Conclusions: This study highlights the importance of studying the interaction between sex and genetic background to determine the risk of DOX-induced cardiotoxicity. In addition, our findings suggest that DOX-induced nephrotoxicity may play a role in DOX-induced cardiac dysfunction in rodent models.

AB - Background: Doxorubicin (DOX) is a very effective anticancer medication that is commonly used to treat hematological malignancies and solid tumors. Nevertheless, DOX is known to have cardiotoxic effects that may lead to cardiac dysfunction and failure. In experimental studies, female animals have been shown to be protected against DOX-induced cardiotoxicity; however, the evidence of this sexual dimorphism is inconclusive in clinical studies. Therefore, we sought to investigate whether genetic background could influence the sexual dimorphism of DOX-induced cardiotoxicity. Methods: Male and female Wistar Kyoto (WKY) and Spontaneous Hypertensive Heart Failure (SHHF) rats were used. DOX was administered in eight doses of 2 mg/kg/week and the rats were followed for an additional 12 weeks. Cardiac function was assessed by trans-thoracic echocardiography, systolic blood pressure was measured by the tail cuff method, and heart and kidney tissues were collected for histopathology. Results: Female sex protected against DOX-induced weight loss and increase in blood pressure in the WKY rats, whereas it protected against DOX-induced cardiac dysfunction and the elevation of cardiac troponin in SHHF rats. In both strains, female sex was protective against DOX-induced nephrotoxicity. There was a strong correlation between DOX-induced renal pathology and DOX-induced cardiac dysfunction. Conclusions: This study highlights the importance of studying the interaction between sex and genetic background to determine the risk of DOX-induced cardiotoxicity. In addition, our findings suggest that DOX-induced nephrotoxicity may play a role in DOX-induced cardiac dysfunction in rodent models.

KW - Cardiotoxicity

KW - Doxorubicin

KW - Sexual dimorphism

UR - http://www.scopus.com/inward/record.url?scp=85041397204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041397204&partnerID=8YFLogxK

U2 - 10.1186/s40959-016-0013-3

DO - 10.1186/s40959-016-0013-3

M3 - Article

SN - 2057-3804

VL - 2

JO - Cardio-Oncology

JF - Cardio-Oncology

IS - 1

M1 - 4

ER -

The interplay between genetic background and sexual dimorphism of doxorubicin-induced cardiotoxicity

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this